Outcome of non-metastatic male breast cancer: 118 patients

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 554-560

  Arslan, Ülkü Yalçintaş ^a   Öksüzoǧlu, Berna ^a   Özdemir, Nuriye ^b   Aksoy, Sercan ^b   Alkiş, Necati ^a   Gök, Ayşe ^a   Kaplan, Mehmet Ali ^c   Gümüş, Mahmut ^d   Berk, Veli ^e   Uncu, Doǧan ^b   Baykara, Meltem ^f   Çolak, Dilşen ^g   Üyetürk, Ümmügül ^a   Türker, Iibrahim ^a   Işikdoǧan, Abdurrahman ^b  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^e ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^f GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^g DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adjuvant; Male breast carcinoma; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; COLLOID CARCINOMA; ENZYME IMMUNOASSAY; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84866305354     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9978-9     Document Type: Article

References (45)

1. SEER Stat Fast Stats: Breast http://seer.cancer.gov/csr/1975-2007.
2. Haydaroǧlu A, Dubova S, Özsaran Z, Bölükbaş i{dotless} Y, Yi{dotless}lmaz R, Kapkaç M, et al. Breast cancer in Ege University "evaluation of 3897 cases". J Breast Health. 2005;1:6-11.
3. Stang A, Thomssen C. Decline in breast cancer incidence in the United states: what about male breast cancer? Breast Cancer Res Treat. 2008;112:595-6.
4. International Agency for Research in Cancer. Cancer Mondial database, Cancer Incidence in 5 Continents (CI5, vol 1-9). [http://www-dep.iarc.fr] website.
5. Giordano S, Cohen D, Buzdar A, Perkins G, Hortobagyi G. Breast carcinoma in men a population-based study. Cancer. 2004; 101:51-7.
6. Fentiman I, Fourquet A, Hortobagyi G. Male breast cancer. Lancet. 2006;367:595-604.
7. Yi{dotless}ldi{dotless}ri{dotless}m E, Berberoǧlu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol. 1998;24:548-52.
8. Patel HZ II, Buzdar A, Hortobagyi G. Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989;64:1583-5.
9. Giordano S, Perkins G, Broglio K, Garcia S, Middleton L, Buzdar A, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104:2359-64.
10. Margaria E, Chiusa L, Ferrari L, Dal Canton O, Pich A. Therapy and survival in male breast carcinoma: a retrospective analysis of 50 cases. Oncol Rep. 2000;7:1035-9.
11. Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987;10:55-60.
12. Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery. 1999;126:775-81.
13. Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW. Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg. 1978;188(1):60-5.
14. Salvadori B, Saccozzi R, Manzari A, Andrealo S, Conti R, et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer. 1994;30A:930-5.
15. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multi-institutional survey. Cancer. 1998;83: 498-509.
16. Marchal F, Salou M, Marchal C, Lesur A, Desandes E. Men with breast cancer have same disease-specific and event-free survival as women. Ann Surg Oncol. 2009;16:972-8.
17. Borgen PI, Senie RT, Mckinnon WM, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol. 1997;4:385-8.
18. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
19. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-74.
20. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-502.
21. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2009;20(4):628-35.
22. Cutuli B, Cohen-Solal-Le Nir C, Serin D, Kirova Y, Gaci Z, Lemanski C, et al. Male breast cancer (MBC). Analysis of treatment strategies in 489 cases. Crit Rev Oncol Hematol. 2010;73:246-54.
23. Cutuli B, Lacroze J, Dilhuydy J, Veiten M, De Lafontan B, Marchal C, et al. Male breast cancer: results of the treatments and prognostics factors in 397 cases. Eur J Cancer. 1995;31:1960-4.
24. Schaub N, Maloney N, Schineider H, Feliberti E, Perry R. Changes in male breast cancer over a 30-year period. Am Surg. 2008;74:707-11.
25. Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer. 1999; 85:629-39.
26. Ribeiro G. Male breast carcinoma-a review of 301 cases from the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer. 1985;511:115-9.
27. Guinee V, Olsson H, Moller T, Shallenberger R, van den Blink J, et al. The prognosis of breast cancer in males. Cancer. 1993;71: 154-61.
28. Walshe J, Berman A, Vatas U, Steinberg S, Anderson W, Lippman M, et al. A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat. 2007;103:177-83.
29. Erlichman C, Murphy K, Elhakim T. Male breast cancer: a 13-year review of 89 patients. J Clin Oncol. 1984;8:903-9.
30. Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley G, et al. Male breast carcinoma: an evaluation of prognostic factors contrubuting to a poorer outcome. Cancer. 1996;77:490-8.
31. Borgen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, Kinne DW, et al. Current management of male breast cancer. A review of 104 cases. Ann Surg. 1992;215:451-9.
32. Anderson WF, Jatoi I, Tse J, Rosenberg RS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28:232-9.
33. Giardano S, Buzdar A, Hortobagyi G. Breast cancer in men. Ann Intern Med. 2002;137:678-87.
34. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, et al. Multidisiplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28:2114-22.
35. Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, Guo M. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res. 2009;11:R28. Epub 2009 May 14.
36. Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol. 2002;15:853-61.
37. Avisar E, McParland E, Dicostanzo D, Axelrod D. Prognostic factors in node-negative male breast cancer. Clin Breast Cancer. 2006;7:331-5.
38. Haffty BG, Yang Q, Kearney T, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:565-7.
39. Foerster R, Foerster FG, Wulff V, Schubotz B, Lange R, Habeck J, Baaske D, Rudlowski C. The clinical significance of triplenegative breast cancer in men (MBC) 2009 breast cancer symposium. Abstract no:63.
40. Hartveit F, Dobbe G, Thoresen S, Dahl O, Tangen M, Thorsen T. The changing pattern of recurrence in oestrogen positive and negative breast cancer with nodal spread, related to efferent vascular invasion. Oncology. 1983;40(2):81-4.
41. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-34.
42. Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001;182:389-92.
43. Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med. 2003;127:36-41.
44. Rudlowski C, Friedrichs N, Faridi A, et al. HER-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res. 2004;84:215-23.
45. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987; 235:177-82.